Detox your domain with our chemical-free home handbook
Article content
Consider exploring some do-it-yourself cleaning alternatives using simple, natural ingredients like vinegar, baking soda, lemon juice, sal suds and essential oils. DIY cleaning solutions can often be more cost-effective than ready-made products and provide excellent results while allowing you to control the ingredients you use.
Article content
One of the biggest chemical culprits in the cleaning world is laundry soap, which can be replaced with a mixture of castille soap, borax, sal suds, washing soda and essential oils. Surface cleaner is another easy one — just soak citrus peels in vinegar and a week later you have a potent countertop spray. A quick search online for a cleanser for your specific task will result in myriad options. Often, many recipes will use the same base ingredients, so one purchase of a few staples will cover chemical-free formulas for your whole home.
Article content
Get picky about packaging
Article content
If you're shopping for cleaning products, look for brands that offer refill options or concentrate formulas to reduce waste and minimize your environmental impact. There are even new options like natural laundry detergent sheets which are lighter to ship, smaller to store and environmentally friendly.
Article content
Beyond consumer goods, consider the packaging of the containers and vessels you choose to bring into your home, and opt for paper or glass materials over plastic as plastic can contain phthalates that leech into plastics and the air. One place to start making the swap from plastic to glass is with your food storage containers. These OXO rectangular containers are perfect for lunch or snacks, while these big Pyrex round containers are great for leftovers.
Article content
Ditching air fresheners and aerosol products, such as hairsprays, dry shampoos and deodorants, is crucial for maintaining a healthy indoor environment and improving indoor air quality. Aerosol products release tiny particles and harmful chemicals into the air, which can lead to respiratory issues and aggravate existing conditions like asthma or allergies.
Purify your air
Article content
Bringing plants into your home can significantly improve its health and contribute to a more chemical-free environment — and make it look cute! Plants naturally filter the air by absorbing carbon dioxide and releasing oxygen through photosynthesis. By introducing plants into your living spaces, you can improve air quality and reduce the presence of pollutants such as formaldehyde, benzene and trichloroethylene, which are commonly found in household items like furniture, carpets and cleaning products. Plus, plants contribute to a calming and stress-reducing atmosphere, promoting overall well-being.
Article content
In addition to plants, air purifiers can also play a vital role in creating a chemical-free cocoon. These devices use filters to trap airborne particles and pollutants, effectively removing them from the air. Seeking a purifier for your home? Look no further than the Dyson Purifier Hot and Cold (read our full review here) which works year-round to heat in the winter and cool in the summer.
Article content
Embrace a shoe-free policy in your home. Why? Shoes can track in dirt, dust, allergens and various contaminants from outside, spreading them throughout your home. By removing shoes at the entrance — or better yet, outside — you can help prevent pollutants from settling on your floors, carpets and furniture. This simple practice can not only maintain a cleaner living space, it'll reduce the need for constant cleaning, and ultimately improve indoor air quality. Not to mention, keeping shoes off indoors can extend the lifespan of your floors and minimize the use of cleaning chemicals.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 hours ago
- Globe and Mail
Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral Report
ROCKVILLE, Md. and SUZHOU, China, June 02, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that it has released the latest data from a Phase Ib/II study of the investigational Bcl-2 inhibitor, lisaftoclax (APG-2575), in combination with hypomethylating agent azacitidine in patients with treatment-naïve (TN) or prior venetoclax-exposed myeloid malignancies, in an oral presentation at the 61st American Society of Clinical Oncology (ASCO) Annual Meeting. The ASCO Annual Meeting showcases the most cutting-edge research in clinical oncology and state-of-the-art advanced cancer therapies and is the world's most influential and prominent scientific gathering of the clinical oncology community. As Ascentage Pharma returns to the ASCO Annual Meeting for the eighth consecutive year, two studies of lisaftoclax and MDM2-p53 inhibitor alrizomadlin (APG-115), key drug candidates in the company's apoptosis-targeted pipeline, have been selected for presentations, including an oral presentation. This oral presentation reported results from a multi-country, multi-center Phase Ib/II study of lisaftoclax, which as of data cutoff in April 2025, enrolled a total of 103 patients, including patients with TN or relapsed/refractory (R/R) acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). Findings of this study once again underscored the promising antitumor activity and manageable tolerability of lisaftoclax in myeloid malignancies. Furthermore, for the first time, this study reported responses in venetoclax-refractory patients who received lisaftoclax, thus suggesting that lisaftoclax has favorable antitumor activity and is differentiated from other drugs in the same class. Lisaftoclax is a novel Bcl-2 inhibitor developed by Ascentage Pharma. In November 2024, the New Drug Application (NDA) for lisaftoclax for the treatment of R/R chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) was accepted and granted a Priority Review designation by the Center for Drug Evaluation (CDE) of China's National Medical Product Administration (NMPA). With this submission, lisaftoclax has become the first China-developed Bcl-2 inhibitor to reach NDA submission in China, and the second Bcl-2 inhibitor with submitted NDAs anywhere in the world. At present, lisaftoclax is being evaluated in four global registrational Phase III studies in major indications such as CLL/SLL, AML, and MDS, including a US Food and Drug Administration (FDA)-cleared multi-country, registrational Phase III trial. Patricia Kropf, MD, Principal Investigator of the study from Novant Health Cancer Institute, commented, 'In this global, multicenter study, lisaftoclax in combination with azacitidine showed promising efficacy and a tolerable safety profile for patients with treatment-naïve or R/R AML and MDS. This data supports the upcoming Phase III study using the combination therapy for this patient population. Interestingly, lisaftoclax showed the potential to overcome resistance to venetoclax in patients who failed prior treatment with venetoclax, suggesting that it might bring improved treatment outcome. We look forward to releasing more data from this study which will further validate lisaftoclax's broad therapeutic potential.' Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma, said, 'In previous studies, lisaftoclax combined with azacitidine has already demonstrated significant activity in patients with various myeloid malignancies. In this oral presentation, we report the latest data from a multi-country, multicenter Phase Ib/II study that showed promising antitumor activity and good tolerability of the combination regimen in myeloid malignancies such as AML and MDS. In particular, lisaftoclax has shown therapeutic potential in venetoclax-refractory patients, making this study the first that reported a Bcl-2 inhibitor overcoming drug resistance to another Bcl-2 inhibitor, thus suggesting that lisaftoclax may bring about a breakthrough to the treatment of myeloid malignancies. For now, lisaftoclax is being evaluated in multi-countries, registrational Phase III studies in AML and MDS. We remain committed to our mission of addressing unmet clinical needs in China and around the world and plan to further accelerate our clinical programs to bring more novel therapeutics to patients as soon as possible.' Highlights of this abstract selected for presentation at ASCO 2025 are as follows: Phase 1b/2 Study of Lisaftoclax (APG-2575) Combined with Azacitidine (AZA) in Patients with Treatment-Naïve or Prior Venetoclax-Exposed Myeloid Malignancies Abstract #: 6505 Format: Oral Presentation Session Title: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant Principal Authors: Michael Francis Leahy, MBChB, Royal Perth Hospital, Australia; Shaun Fleming, MBBS(Hons), PhD, The Alfred Hospital & Australian Centre for Blood Diseases, Australia; Patricia Kropf, MD, Novant Health Cancer Institute, United States, et al. Highlights: Background: AML and MDS are hematologic malignancies with poor prognoses. Hypomethylating agents (HMAs) AZA and decitabine are approved for MDS and AML and have been shown to prolong survival in patients. However, additional treatment options that improve clinical outcomes, such as complete response (CR) and overall survival (OS), are needed. Lisaftoclax is an investigational, orally active, small-molecule Bcl-2 inhibitor that has shown enhanced treatment responses in AML and MDS when combined with AZA in preclinical 1 and clinical 2 studies. Efficacy results: As of the data cutoff in April 2025, 22 of 28 venetoclax-refractory patients with R/R AML/ Mixed Phenotype Acute Leukemia (MPAL) were efficacy-evaluable, among whom, the overall response rate (ORR) was 31.8%, including 22.8%, 4.6%, and 4.6% achieving CR/CR with incomplete hematologicrecovery (CRi), partial response (PR), and the morphologic leukemia-free state (MLFS), respectively. All responsive patients had received multiple lines of therapy that included venetoclax, and most of them (71%, 5/7) harbored the TP53 mutation and had a complex chromosomal karyotype at baseline. In 6 efficacy-evaluable patients with newly diagnosed (ND) AML/MPAL, the ORR was 83.3%, with CR/CRi and PR achieved by 33.3% and 50% of patients, respectively. In 44 efficacy-evaluable patients with R/R AML/MPAL, the ORR was 43.2%, with CR/CRi, PR, and MLFS achieved by 31.8%, 4.5%, and 6.8% of patients, respectively. In 15 efficacy-evaluable patients with ND MDS/chronic myelomonocytic leukemia (CMML), the ORR was 80%, with CR and marrow CR (mCR) achieved by 40% and 40% of patients, respectively. In 22 efficacy-evaluable patients with R/R MDS/CMML, the ORR was 50%, with CR, mCR, and PR achieved by 27.3%, 18.2%, and 4.5% of patients, respectively. Safety results: Lisaftoclax in combination with AZA was well tolerated, with a manageable profile. Common adverse events were mostly hematologic. Nonhematologic toxicity was uncommon. The majority of adverse events were manageable, reversible and tolerable. Conclusions: Lisaftoclax combined with AZA showed promising antitumor activity and favorable tolerability in patients with TN or R/R myeloid malignancies. Furthermore, lisaftoclax demonstrated the ability to overcome drug resistance to venetoclax, making this the first clinical study to report a Bcl-2 inhibitor overcoming venetoclax resistance. * Lisaftoclax (APG-2575) is an investigational compound and has not been approved by the US FDA. Reference: 1 Zhai Y, Tang Q, Fang DD, et al. Lisaftoclax in Combination with Alrizomadlin Overcomes Venetoclax Resistance in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Preclinical Studies. Clin Cancer Res. 2023;29:183-196. 2 Wang H, Wei X, Jiang Q, et al. Safety and Efficacy of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i), in Relapsed or Refractory (R/R) or Treatment-Naïve (TN) Patients (Pts) with Acute Myeloid leukemia (AML), Myelodysplastic Syndrome (MDS), or Other Myeloid Neoplasms. Blood 2023;142(Suppl 1):2925. About Ascentage Pharma Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855) is a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers. The company has built a rich pipeline of innovative drug candidates that includes inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53 and next-generation kinase inhibitors. The lead asset, olverembatinib, is the first third generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or POLARIS-2, of olverembatinib for CML, as well as global registrational Phase III trials for newly diagnosed Ph + ALL patients and SDH-deficient GIST patients. The second lead asset, lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematological malignancies. The NDA for the treatment of relapsed and/or refractory CLL and SLL was accepted with Priority Review designation by China's National Medical Products Administration. The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or GLORA, of lisaftoclax in combination with BTK inhibitors for patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with sub-optimal response, as well as global registrational Phase III trials for newly diagnosed CLL/SLL, AML and MDS patients. Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit Forward-Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma's filings with the SEC, including those set forth in the sections titled 'Risk factors' and 'Special note regarding forward-looking statements and industry data' in its Registration Statement on Form F-1, as amended, filed with the SEC on January 21, 2025, and the Form 20-F filed with the SEC on April 16, 2025, the sections headed 'Forward-looking Statements' and 'Risk Factors' in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited we made or make from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation do not constitute profit forecast by the Company's management. As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma's current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Contacts Investor Relations: Hogan Wan, Head of IR and Strategy Ascentage Pharma +86 512 85557777 Stephanie Carrington ICR Healthcare +1 (646) 277-1282 Media Relations: Sean Leous ICR Healthcare +1 (646) 866-4012
Globe and Mail
4 hours ago
- Globe and Mail
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on June 2, 2025, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to purchase an aggregate of 137,400 shares of the Company's common stock to four (4) newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual's entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4). The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Zentalis, or following a bona fide period of non-employment, as an inducement material to each such individual's entering into employment with Zentalis, pursuant to Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $1.28 per share, which is equal to the closing price of Zentalis' common stock on The Nasdaq Global Market on the date of grant. The stock options have a 10-year term and will vest over four years, with 25% of the options vesting on the first anniversary of the vesting commencement date and the remaining 75% of the options vesting in equal monthly installments over the three years thereafter. Vesting of the stock options is subject to the employees' continued service to Zentalis on each vesting date. About Zentalis Pharmaceuticals Zentalis® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). Azenosertib is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials and has broad franchise potential. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. The Company is also leveraging its extensive experience and capabilities to translate its science to advance research on additional areas of opportunity for azenosertib outside PROC. Zentalis has operations in San Diego.
Globe and Mail
5 hours ago
- Globe and Mail
AGI Releases 2024 Sustainability Report
Ag Growth International Inc. (TSX: AFN) ('AGI', the 'Company', 'we', or 'our') today released its 2024 Sustainability Report. The report highlights AGI's recent performance and achievements across a range of sustainability-related topics. 'I am pleased to present our 2024 Sustainability Report, which showcases our recent achievements in sustainability, including our unwavering commitment to global food security, record safety performance, and progress in reducing greenhouse gas emissions intensity,' commented Paul Householder, President & CEO of AGI. 'I am inspired by the dedication and efforts of our global workforce to advance our sustainability strategy and related goals. Over the past year, we have made measurable progress in reducing our environmental impact, fostering a safe and inclusive culture, and upholding the highest standards of governance and ethics. By driving these initiatives forward, we are enhancing the long-term resilience of our business.' Highlights from the report include progress on employee safety, greenhouse gas (GHG) emissions, and employee engagement, among others. Key highlights include: Details of AGI's contribution to support global food security Significant improvements in safety performance, with a reduction in our Lost Time Incident Rate 1 by 46% and in our Total Recordable Incident Rate 2 by 49% from 2023 levels Reduced our Scope 1 and 2 greenhouse gas (GHG) emissions intensity by 16%, on track to achieve our target of reducing intensity by 25% by 2030 Achieved 100% compliance on AGI's annual employee ethics confirmation in 2024 Over 96% of our global workforce completed training on unconscious bias The full 2024 Sustainability Report is available on AGI's website here. AGI Company Profile AGI is a provider of the equipment and solutions required to support the efficient storage, transport, and processing of food globally. AGI has manufacturing facilities in Canada, the United States, Brazil, India, France, and Italy and distributes its product worldwide. Forward-Looking Information: This document contains certain forward-looking information. More particularly and without limitation, this document contains forward-looking information regarding AGI's target to reduce our Scope 1 and 2 GHG emissions intensity by 25% by 2030, compared to our 2021 baseline. This forward-looking information is based on a number of factors and assumptions which have been used to develop such information including, among other things: our ability to continue to implement and the success of our sustainability programs, the timing thereof and the impact on AGI achieving its goals and targets relating thereto; our ability to improve the energy intensity of our manufacturing operations; our ability to manage and reduce our energy consumption; our ability to reduce GHG emissions and GHG emissions intensity; the availability of the capital, labour and services required to successfully implement our sustainability programs on the timetable anticipated and to achieve our related goals; the cost to implement and maintain our sustainability programs; our ability to successfully partner with third parties to implement our sustainability programs; the availability of renewable energy such as solar in the areas that we operate; our ability to successfully advance and/or implement technology and innovation into our operations; and the sufficiency of budgeted capital expenditures in carrying out planned sustainability activities. Readers are cautioned that the foregoing list is not exhaustive of all factors and assumptions which have been used. Although AGI believes that the factors and assumptions on which the forward-looking information are based are reasonable, undue reliance should not be placed on the forward-looking information because AGI can give no assurance that they will prove to be correct. Since forward-looking information addresses future events and conditions, by its very nature it involves inherent risks and uncertainties, most of which are beyond our control. Actual results could differ materially from those currently anticipated due to a number of risks and uncertainties. These risks and uncertainties include, but are not limited to: the risk that we are unable to implement our sustainability programs in part or in full and/or on the anticipated timetable and/or that they are not successful in accomplishing our sustainability goals; the risk that we are unable to improve the energy intensity of our manufacturing operations materially or at all; the risk that we are unable to reduce our energy consumption materially or at all; the risk that we are unable to reduce GHG emissions and/or GHG emissions intensity materially or at all; the risk that the capital, labour and/or services required to successfully implement our sustainability programs are not available in part or at all and that as a result we are unable to achieve our sustainability goals on the anticipated timetable or at all; the risk that the cost to implement and maintain our sustainability programs is higher than currently anticipated or subsequently increases such that the implementation and/or maintenance of one or more of such sustainability programs becomes uneconomic; the risk that we determine to allocate our financial, managerial and/or operational resources to priorities other than the achievement of our sustainability goals due to factors outside of our control or otherwise; the risk that we may not be able to successfully partner with third parties to implement our sustainability programs; and the risk that suitable sources of renewable energy such as solar may not be available in certain areas in which we operate or at all. Readers are cautioned that the foregoing lists of risks and uncertainties is not exhaustive. This forward-looking information are made as of the date of this document and AGI disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws. The forward-looking information contained in this document is expressly qualified by this cautionary statement. 1"Lost Time Incident Rate" is calculated in line with U.S. Occupational Safety and Health Administration (OSHA) standards using the formula: ([number of lost time injuries in the reporting period] x 200,000) / (total hours worked in the reporting period); this metric references the number of lost time injuries per 100 employees per year, assuming a 40-hour work week and 50 weeks worked. 2"Total Recordable Incident Rate" is calculated in line with OSHA standards using the formula: (Number of OSHA recordable incidents in the reporting period) x 200,000 / (total number of hours worked in the reporting period); this metric references the number of recordable incidents per 100 full-time employees annually.
